In 1963, the National Cancer Institute initiated a pilot study to test MOPP (Mechlorethamine, Vincristine, Procarbazine, Prednisone) chemotherapy regimenchemotherapy in 43 patients with advanced Hodgkinﾒs lymphoma (HL). MOPP was the first regimen capable of prolonging DFS in advanced disease and the first such success in any disseminated solid tumor. Providing the same therapeutic benefit as MOPP with less hematologic toxicity and lower rates of infertility, ABVD eventually replaced MOPP as the standard of care for advanced HL in the U.S.